Atara Q2 net loss $4.8M; FDA meeting backs tab-cel BLA resubmission

Atara Biotherapeutics, Inc.

Q2 2026 net loss of $4.8M ($0.32/share) vs net income of $2.4M in Q2 2025.
Total revenues $0.6M vs $17.6M YoY, down $17.0M on deferred revenue acceleration.
Cash and short-term investments $9.9M at June 30, 2026; operating expenses down 87% YoY.
Cash runway into mid-2027; productive Type A FDA meeting supports tab-cel BLA resubmission.
Eligible for $31M milestone on FDA approval plus tiered royalties on EBVALLO sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.